Clinical Evaluation of a Progressive Addition Lens (PAL)
Primary Purpose
Presbyopia
Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Progressive Addition Lens (Shamir PrimeIITM) Spectacles
Sponsored by
About this trial
This is an interventional treatment trial for Presbyopia focused on measuring Progressive Addition Lens, Multifocal, Presbyopia
Eligibility Criteria
Inclusion Criteria:
- An ability to comprehend and give an informed consent for participation in the trial
- Presbyopia
Exclusion Criteria:
- Concurrent participation in another clinical trial
- Age<18
- For female subjects: pregnancy \ planning a pregnancy \ lactating at the time of enrollment
- Imbalanced diabetes \ high blood pressure \ thyroid disease
- Infectious disease
- Inability (cognitively) to comprehend the instructions given during the trial and to comply with them
Sites / Locations
Outcomes
Primary Outcome Measures
Horizontal Intermediate Visual Field
Visual Acuity
Horizontal Near Visual Field
Field of comfortable reading on a computer screen
Horizontal Far Visual Field
Secondary Outcome Measures
Subjective Evaluation of Visual Quality
Overall Subjective Feedback
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01443585
Brief Title
Clinical Evaluation of a Progressive Addition Lens (PAL)
Official Title
Clinical Performance Evaluation of a Progressive Addition Lens Among Presbyopic Patients
Study Type
Interventional
2. Study Status
Record Verification Date
September 2011
Overall Recruitment Status
Unknown status
Study Start Date
September 2012 (undefined)
Primary Completion Date
November 2013 (Anticipated)
Study Completion Date
undefined (undefined)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ziv Hospital
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of the trial is to clinically evaluate the performance of a progressive addition lens among presbyopic patients.
This evaluation will be done by performing visual tests and collecting subjective information from subjects wearing the lens which will be manufactured according to personal prescription.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Presbyopia
Keywords
Progressive Addition Lens, Multifocal, Presbyopia
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
100 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Device
Intervention Name(s)
Progressive Addition Lens (Shamir PrimeIITM) Spectacles
Intervention Description
A pair of progressive addition lenses manufactured according to the subject's personal prescription.
Primary Outcome Measure Information:
Title
Horizontal Intermediate Visual Field
Time Frame
Baseline
Title
Visual Acuity
Time Frame
Baseline
Title
Horizontal Near Visual Field
Time Frame
Baseline
Title
Field of comfortable reading on a computer screen
Time Frame
Baseline
Title
Horizontal Far Visual Field
Time Frame
Baseline
Secondary Outcome Measure Information:
Title
Subjective Evaluation of Visual Quality
Time Frame
2-3 weeks
Title
Overall Subjective Feedback
Time Frame
2-3 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
An ability to comprehend and give an informed consent for participation in the trial
Presbyopia
Exclusion Criteria:
Concurrent participation in another clinical trial
Age<18
For female subjects: pregnancy \ planning a pregnancy \ lactating at the time of enrollment
Imbalanced diabetes \ high blood pressure \ thyroid disease
Infectious disease
Inability (cognitively) to comprehend the instructions given during the trial and to comply with them
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Yosef Pikel, M.D
Organizational Affiliation
Ziv Medical Center, Zefat, Israel
Official's Role
Principal Investigator
12. IPD Sharing Statement
Learn more about this trial
Clinical Evaluation of a Progressive Addition Lens (PAL)
We'll reach out to this number within 24 hrs